Apotex asks Supreme Court to overturn Teva ‘Bendeka’ ruling
Apotex has asked the US Supreme Court to reconsider a US Court of Appeals for the Federal Circuit ruling upholding four of Teva Pharmaceutical’s cancer drug patents.
BioDelivery Sciences ‘pleased’ with mixed ruling over Opioid drug claims
A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ opioid medication Belbuca, but invalidated others.
NextCure targeted in cancer drug trade secrets suit
Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.
Gilead, BMS, Janssen facing HIV generic antitrust suit
Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.
Intubated patients sedative patent the focus of ACS Dobfar suit
Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.
3M stumbles in litigation strategy over COVID-19 masks
Multinational 3M has suffered a setback in its litigation campaign against the distributors of N95 masks after a US judge found in favour of arguments made by one of its opponents.
Generics win anti-pay-for-delay bill challenge
The Association for Accessible Medicines, which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.
Pharmavite accuses Bausch, GSK of ‘sham’ patent litigation
Nutritional supplements manufacturer Pharmavite has filed an antitrust suit against Bausch & Lomb and GlaxoSmithKline, claiming that they are filing sham patent litigation related to its “PreserVision” products.
GSK responds to Teva’s ‘skinny’ label rehearing petition
Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne has added its response to the petition to rehear the case yet again.
Teva loses appeal to invalidate Korlym patent
Teva Pharmaceuticals has failed to convince the US Court of Appeal for the Federal Circuit that a Corcept Therapeutics method patent for Korlym was invalid.
